Ignite Creation Date:
2024-05-05 @ 6:31 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00499993
Status:
COMPLETED
Last Update Posted:
2019-01-15
First Post:
2007-07-11
Brief Title:
Efficacy and Tolerability of Lanreotide Autogel 120 mg in Patients With Acromegaly
Sponsor:
Ipsen
Organization:
Ipsen
Study Overview
Official Title:
Phase III Multicentre Open Clinical Study on the Efficacy and Tolerability of a New Slow-release Formulation of Lanreotide Autogel 120 mg in Patients With Active Acromegaly
Status:
COMPLETED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the protocol is to evaluate if lanreotide Autogel 120 mg is effective in the control of Growth Hormone GH secretion in patients with active acromegaly
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None